Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
June 26, 2024Effective PharmacotherapyOpen Access

Beyond Glycemic Control: Pleiotropic Effects of Sitagliptin

View Full Paper
Ask AI
Bookmark
Share

Authors

ОДО. Д. ДыгунАВА.Р. ВолковаYKYu. Sh. Khalimov

Discussion

Loading...

Member takes

Overview

Review shows pleiotropic benefits of sitagliptin across cardiovascular, renal, and metabolic systems in type 2 diabetes mellitus, highlighting therapeutic applications beyond glycemic control.

Key Points

  • Sitagliptin extends therapeutic action beyond glycemic control in type 2 diabetes mellitus, reducing cardiovascular complications while favorably altering the blood lipid spectrum.
  • Review of clinical trials reveals that sitagliptin slows chronic kidney disease progression and may effectively mitigate liver fibrosis across diverse patient cohorts.
  • Highlights multi-organ protective effects, suggesting sitagliptin may provide therapeutic utility for immune system disorders alongside nervous and reproductive dysfunction.

Cite This Study

Дыгун et al. (2024) studied this question.

synapsesocial.com/papers/68e634d1b6db6435875c679ehttps://doi.org/10.33978/2307-3586-2024-20-13-32-36
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sitagliptin: A Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes2006 · 102 citations
  2. 2Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study2017 · 12 citations
  3. 3Sitagliptin is a time-tested leading drug in the treatment of type 2 diabetes2024
  4. 4ADVANTAGES, SAFETY AND PROSPECTS OF SITAGLIPTIN APPLICATION IN TYPE 2 DIABETES MELLITUS WITH CHRONIC KIDNEY DISEASE2017
  5. 5SUBCLINICAL INFLAMMATION; ANTI INFLAMMATORY EFFECT OF SITAGLIPTIN IN TYPE 2 DIABETIC DYSLIPIDEMIC PATIENTS2016